SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1603.0
(0.25%)
KRW 1603.0
(0.25%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 101.81 Million KRW | -85.87% |
| 2022 | 720.65 Million KRW | -34.6% |
| 2021 | 1.1 Billion KRW | -77.36% |
| 2020 | 4.86 Billion KRW | 280.02% |
| 2019 | 1.28 Billion KRW | -40.42% |
| 2018 | 2.14 Billion KRW | -56.18% |
| 2017 | 4.9 Billion KRW | -69.92% |
| 2016 | 16.3 Billion KRW | -69.93% |
| 2015 | 54.23 Billion KRW | 1497.59% |
| 2014 | 3.39 Billion KRW | -81.12% |
| 2013 | 17.98 Billion KRW | -38.26% |
| 2012 | 29.13 Billion KRW | 279.72% |
| 2011 | 7.67 Billion KRW | 33.74% |
| 2010 | 5.73 Billion KRW | 3339.4% |
| 2009 | 166.78 Million KRW | 196.38% |
| 2008 | 56.27 Million KRW | -4.07% |
| 2007 | 58.66 Million KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 153.87 Million KRW | -100.0% |
| 2024 Q2 | 118.63 Million KRW | 0.0% |
| 2023 Q1 | 520.44 Million KRW | -27.78% |
| 2023 Q4 | 101.81 Million KRW | -67.94% |
| 2023 Q3 | 317.61 Million KRW | -14.52% |
| 2023 FY | 101.81 Million KRW | -85.87% |
| 2023 Q2 | 371.54 Million KRW | -28.61% |
| 2022 Q3 | 696.81 Million KRW | -17.94% |
| 2022 FY | 720.65 Million KRW | -34.6% |
| 2022 Q4 | 720.65 Million KRW | 3.42% |
| 2022 Q1 | 1 Billion KRW | -8.83% |
| 2022 Q2 | 849.18 Million KRW | -15.47% |
| 2021 Q4 | 1.1 Billion KRW | 1533.15% |
| 2021 Q3 | 67.47 Million KRW | -28.74% |
| 2021 Q2 | 94.68 Million KRW | 15.58% |
| 2021 Q1 | 81.91 Million KRW | -98.32% |
| 2021 FY | 1.1 Billion KRW | -77.36% |
| 2020 Q3 | 5.07 Billion KRW | -4.61% |
| 2020 Q1 | 1.02 Billion KRW | 0.0% |
| 2020 Q2 | 5.31 Billion KRW | 416.59% |
| 2020 Q4 | 4.86 Billion KRW | -4.07% |
| 2020 FY | 4.86 Billion KRW | 280.02% |
| 2019 FY | 1.28 Billion KRW | -40.42% |
| 2019 Q1 | 2.12 Billion KRW | -1.22% |
| 2019 Q2 | 1.83 Billion KRW | -13.61% |
| 2019 Q3 | 1.42 Billion KRW | -22.5% |
| 2018 Q1 | 4.66 Billion KRW | -4.92% |
| 2018 Q4 | 2.14 Billion KRW | -48.59% |
| 2018 Q2 | 4.42 Billion KRW | -5.18% |
| 2018 FY | 2.14 Billion KRW | -56.18% |
| 2018 Q3 | 4.18 Billion KRW | -5.46% |
| 2017 FY | 4.9 Billion KRW | -69.92% |
| 2017 Q4 | 4.9 Billion KRW | -12.89% |
| 2017 Q3 | 5.63 Billion KRW | -19.62% |
| 2017 Q2 | 7 Billion KRW | -11.38% |
| 2017 Q1 | 7.9 Billion KRW | -51.51% |
| 2016 FY | 16.3 Billion KRW | -69.93% |
| 2016 Q4 | 16.3 Billion KRW | -6.68% |
| 2016 Q3 | 17.47 Billion KRW | 1.12% |
| 2016 Q2 | 17.28 Billion KRW | -66.34% |
| 2016 Q1 | 51.34 Billion KRW | -5.31% |
| 2015 Q2 | 22.81 Billion KRW | 0.0% |
| 2015 Q3 | 36.94 Billion KRW | 61.97% |
| 2015 Q4 | 54.23 Billion KRW | 46.78% |
| 2015 FY | 54.23 Billion KRW | 1497.59% |
| 2014 FY | 3.39 Billion KRW | -81.12% |
| 2014 Q4 | 3.39 Billion KRW | 0.0% |
| 2014 Q1 | 17.91 Billion KRW | -0.41% |
| 2013 FY | 17.98 Billion KRW | -38.26% |
| 2013 Q4 | 17.98 Billion KRW | -9.66% |
| 2013 Q3 | 19.9 Billion KRW | -1.31% |
| 2013 Q2 | 20.17 Billion KRW | -5.64% |
| 2013 Q1 | 21.37 Billion KRW | -26.62% |
| 2012 Q1 | 14.9 Billion KRW | 94.24% |
| 2012 Q2 | 14.79 Billion KRW | -0.71% |
| 2012 Q3 | 15.16 Billion KRW | 2.5% |
| 2012 Q4 | 29.13 Billion KRW | 92.09% |
| 2012 FY | 29.13 Billion KRW | 279.72% |
| 2011 Q4 | 7.67 Billion KRW | -0.22% |
| 2011 Q2 | 7.7 Billion KRW | 34.68% |
| 2011 Q1 | 5.72 Billion KRW | -0.27% |
| 2011 Q3 | 7.68 Billion KRW | -0.21% |
| 2011 FY | 7.67 Billion KRW | 33.74% |
| 2010 Q2 | 3.68 Billion KRW | 2304.09% |
| 2010 Q3 | 174.4 Million KRW | -95.27% |
| 2010 Q4 | 5.73 Billion KRW | 3189.01% |
| 2010 Q1 | 153.47 Million KRW | -7.98% |
| 2010 FY | 5.73 Billion KRW | 3339.4% |
| 2009 Q3 | 177.31 Million KRW | 222.69% |
| 2009 Q1 | 55.62 Million KRW | -1.16% |
| 2009 Q4 | 166.78 Million KRW | -5.94% |
| 2009 Q2 | 54.94 Million KRW | -1.21% |
| 2009 FY | 166.78 Million KRW | 196.38% |
| 2008 Q2 | 57.51 Million KRW | -1.01% |
| 2008 Q3 | 56.9 Million KRW | -1.06% |
| 2008 Q4 | 56.27 Million KRW | -1.11% |
| 2008 FY | 56.27 Million KRW | -4.07% |
| 2008 Q1 | 58.09 Million KRW | -0.96% |
| 2007 Q3 | 59.2 Million KRW | -0.88% |
| 2007 FY | 58.66 Million KRW | 0.0% |
| 2007 Q4 | 58.66 Million KRW | -0.92% |
| 2007 Q1 | 18.27 Billion KRW | 0.0% |
| 2007 Q2 | 59.72 Million KRW | -99.67% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 99.254% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 99.95% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 99.659% |
| HANDOK Inc. | 123.78 Billion KRW | 99.918% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | 78.598% |
| Yuhan Corporation | 60.23 Billion KRW | 99.831% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 99.937% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 99.876% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | 82.752% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 98.317% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 99.45% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 99.191% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | 93.632% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 99.254% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | 14.924% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 99.916% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 99.682% |
| JW Holdings Corporation | 20.65 Billion KRW | 99.507% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 99.313% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 99.661% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 99.661% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | 53.5% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | 82.465% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 99.795% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | 97.713% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 99.254% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 99.465% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 99.891% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 99.661% |
| Yuhan Corporation | 60.23 Billion KRW | 99.831% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | 99.03% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 99.748% |
| Suheung Co., Ltd. | 74 Billion KRW | 99.862% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 99.661% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | 97.556% |
| Korea United Pharm Inc. | 10.96 Billion KRW | 99.071% |
| CKD Bio Corp. | 69.43 Billion KRW | 99.853% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 99.706% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 99.369% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | 66.841% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | 53.5% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 99.859% |
| Boryung Corporation | 151.7 Billion KRW | 99.933% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 99.87% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 98.317% |
| JW Lifescience Corporation | 168 Million KRW | 39.394% |